WESPAC Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-15,577
Closed -$791K 218
2026
Q1
$791K Buy
+15,577
New +$727K 0.43% 72
2021
Q4
Sell
-1,713
Closed -$659K 171
2021
Q3
$659K Buy
+1,713
New +$632K 0.41% 89
2021
Q2
Sell
-2,161
Closed -$283K 139
2021
Q1
$283K Buy
+2,161
New +$313K 0.21% 128

Other funds holding MRNA

WESPAC Advisors's MRNA Position: Q2 2026 in Review

WESPAC Advisors sold out of Moderna (MRNA) in Q2 2026, closing a stake of 15,577 shares — an estimated $791K sold.

WESPAC Advisors first reported a position in MRNA in Q1 2021 and held it in 3 quarters. The position peaked at $791K in Q1 2026. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • WESPAC Advisors reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • WESPAC Advisors sold 15,577 Moderna shares in Q2 2026, an estimated $791K.
  • WESPAC Advisors first reported a position in Moderna in Q1 2021 and held it in 3 quarters.
  • WESPAC Advisors's Moderna position peaked at $791K in Q1 2026.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on WESPAC Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.